A new multicentre HERO Registry study has confirmed that the Optimed sinus SuperFlex 635 stent delivers excellent clinical outcomes for patients with complex femoropopliteal lesions.
Key highlights from the HERO Registry include:
- 78.5% primary patency at 12 months: The majority of patients experienced continued vessel openness one year after their procedure.
- Exceptionally low stent fracture rate (0.9%): The stent’s robust design minimises complications, ensuring long-term durability.
- Over 88% clinical improvement (Rutherford class 0–1): Most patients saw significant symptom relief and improved quality of life.
The sinus-SuperFlex-635 stent stands out due to its innovative hybrid design, featuring secure closed-cell ends for stability, and a flexible open-cell mid-section for adaptability. This combination makes it a safe and reliable choice for treating challenging femoropopliteal artery lesions.
Discover more about the HERO study and the sinus-SuperFlex-635 stent’s impact on patient care
Contact us for more information
5th – 6th February 2026: The 28th BSGAR Annual Meeting
17th March 2026: UK Biliary Intervention Study Day
23rd – 24th March 2026: Vascular Innovations and Technological Advancements Learning Symposium
7th May 2026: Liver Intervention Study Day
For more information, email Aquilant.newsletter@hc21.group or visit healthcare21.eu/
United Kingdom
Ireland